Metraipolis › archive › dc_329d6337fd9d

Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base — Europe PMC PMID:41704755

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41704755
DOI
10.1016/j.isci.2026.114766
License (as archived)
solo-consultazione
Archived
2026-11-06T15:20:55.281Z
SHA-256 of the archived text
cf326cfaee1131df347104190aaa6a2153a17ade2100f3c0268cff7dafce27c6
Stable URL of this page
https://metraipolis.com/documento/dc_329d6337fd9d

How to cite

Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base — Europe PMC PMID:41704755 — Europe PMC (en), https://europepmc.org/article/MED/41704755 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_329d6337fd9d (Metraipolis archive dc_329d6337fd9d, sha256 cf326cfaee1131df347104190aaa6a2153a17ade2100f3c0268cff7dafce27c6)
BibTeX
@misc{dc329d6337fd9d,
  title = {Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base — Europe PMC PMID:41704755},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41704755},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_329d6337fd9d; sha256 cf326cfaee1131df347104190aaa6a2153a17ade2100f3c0268cff7dafce27c6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41704755. Agents can read the archived copy with the MCP tool read_document.